Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Noveome's multi-target platform biologic and lead product, ST266, is a complex, non-cellular product containing hundreds of biologically active proteins and other biologic factors. ST266 is currently being evaluated in multiple indications across CNS, ophthalmic, pulmonary and gastrointestinal therapeutic areas.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/09/19 | $15,000,000 | Series D |
Commonwealth of Pennsylvania and Allegheny County US Dept of Defense | undisclosed |
